Why do we not have more drugs approved for MDS? A critical viewpoint on novel drug development in MDS
|
Jul 2023
|
Blood Advances
|
myelodysplastic syndromes (MDS)
|
Raising the bar for lower-risk myelodysplastic syndromes
|
Jun 2023
|
Leukemia & Lymphoma
|
myelodysplastic syndromes (MDS)
|
Nationwide study of eculizumab in paroxysmal nocturnal hemoglobinuria: Evaluation of treatment indications and outcomes
|
Jun 2023
|
European Journal of Haematology
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
Complement Inhibition in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Systematic Review and Expert Opinion from Central Europe on Special Patient Populations
|
Jun 2023
|
Advances in Therapy
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
Alemtuzumab in relapsed immune severe aplastic anemia: Long-term results of a phase II study
|
Jun 2023
|
American Journal of Hematology
|
aplastic anemia
|
An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDS
|
Jun 2023
|
Blood Advances
|
myelodysplastic syndromes (MDS)
|
Clonal evolution in aplastic anemia: failed tumor surveillance or maladaptive recovery?
|
Jun 2023
|
Leukemia & Lymphoma
|
aplastic anemia
|
Determinants of low health-related quality of life in patients with myelodysplastic syndromes: EUMDS Registry study
|
Jun 2023
|
Blood Advances
|
myelodysplastic syndromes (MDS)
|
Therapy-related myelodysplastic syndromes in the genomics era
|
Jun 2023
|
Bulletin du Cancer
|
myelodysplastic syndromes (MDS)
|
Treatment of eculizumab refractory paroxysmal nocturnal hemoglobinuria: A systematic review about current treatment options and future direction
|
Jun 2023
|
SAGE Open Medicine
|
paroxysmal nocturnal hemoglobinuria (PNH)
|